TY - JOUR T1 - A novel haemocytometric COVID-19 prognostic score developed and validated in an observational multicentre European hospital-based study JF - medRxiv DO - 10.1101/2020.09.27.20202168 SP - 2020.09.27.20202168 AU - Joachim Linssen AU - Anthony Ermens AU - Marvin Berrevoets AU - Michela Seghezzi AU - Giulia Previtali AU - Simone van der Sar-van der Brugge AU - Henk Russcher AU - Annelies Verbon AU - Judith Gillis AU - Jürgen Riedl AU - Eva de Jongh AU - Jarob Saker AU - Marion Münster AU - Imke CA Munnix AU - Anthonius Dofferhoff AU - Volkher Scharnhorst AU - Heidi Ammerlaan AU - Kathleen Deiteren AU - Stephan JL Bakker AU - Lucas Joost van Pelt AU - Yvette Kluiters-de Hingh AU - Mathie PG Leers AU - André van der Ven Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/09/28/2020.09.27.20202168.abstract N2 - COVID-19 induces haemocytometric changes. Complete blood count changes, including new cell activation parameters, from 982 confirmed COVID-19 adult patients from 11 European hospitals were retrospectively analysed for distinctive patterns based on age, gender, clinical severity, symptom duration and hospital days. The observed haemocytometric patterns formed the basis to develop a multi-haemocytometric-parameter prognostic score to predict, during the first three days after presentation, which patients will recover without ventilation or deteriorate within a two-week timeframe, needing intensive care or with fatal outcome. The prognostic score, with ROC curve AUC at baseline of 0.753 (95% CI 0.723-0.781) increasing to 0.875 (95% CI 0.806-0.926) on day 3, was superior to any individual parameter at distinguishing between clinical severity. Findings were confirmed in a validation cohort. Aim is that the score and haemocytometry results are simultaneously provided by analyser software, enabling wide applicability of the score as haemocytometry is commonly requested in COVID-19 patients.Competing Interest StatementJoachim Linssen, Jarob Saker and Marion Munster are full-time employees of Sysmex Europe GMBH who provided the study reagents free of charge. Andre van der Ven has an ad hoc consultancy agreement with Sysmex Europe GMBH. All other authors having nothing to declare.Funding StatementSysmex Europe GMBH provided study reagents free of charge to all participating study centres.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was reviewed by all participating centre ethics committees with approval granted in Italy (Registration Number 54/20) and Belgium (Registration Number 3002020000105) and exemption in the Netherlands, with need for informed consent waived by all.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSource data files are provided as supplementary material. ER -